Compare Centene Corp (CNC) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Tilray Brands Inc — how do they compare? Centene Corp trades at $66.38 (market cap $32.05B), while Tilray Brands Inc trades at $4.64 (market cap $649.42M). The key difference: Centene Corp is far larger — about 49.4× Tilray Brands Inc's market cap, and Centene Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| CNC | TLRY | |
|---|---|---|
Market Cap | $32.05B | $649.42M |
Sector | Health | Health |
52-Week High | $68.72 | $21.00 |
52-Week Low | $26.17 | $3.88 |
Enterprise Value | $21.10B | $816.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $66.56, up 1.2% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $71.00. The company reported strong Q2 2026 earnings of $2.51 per share, beating estimates, and raised its full-year EPS guidance, reflecting margin recovery and cost discipline. Revenue growth remains robust, projected to reach $202.9 billion in 2026, though net income margins are negative due to elevated medical costs.
The stock presents a value opportunity with low P/E (8.06) and P/S (0.16) ratios, but investors face risks from Medicaid membership volatility and regulatory pressures. Analyst sentiment is strongly bullish (61% buy ratings), with institutional interest growing, as seen in recent fund additions. Near-term upside is likely if cost controls sustain profitability improvements.
TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.
Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
